drugset / Trial / NCT00516477

Safety Study in Subjects With Leber Congenital Amaurosis

NCT00516477 ↗

Phase 1 Completed 12 enrolled Spark Therapeutics, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether gene transfer will be safe and effective in the treatment of Leber Congenital Amaurosis (LCA).

Timeline

Start
2007-09
Primary completion
2018-03-20
Completion
2018-03-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject voretigene neparvovec Unknown 1.5e+10 vg Subcutaneous
Subject voretigene neparvovec Unknown 4.8e+10 vg Subcutaneous
Subject voretigene neparvovec Unknown 1.5e+11 vg Subcutaneous